Protagonist Therapeutics(DE:PGF)
€75.000.00 (0.00%)
DE:PGF
Protagonist Therapeutics stock forecast
€75.00
At close:0.00 (0.00%)
Protagonist Therapeutics (PGF) Stock Forecast & Price Target
1 Followers
PGF Analyst Ratings
Strong Buy
13Buy0Hold0Sell
Based on 13 analysts giving stock ratings to Protagonist Therapeutics in the past 3 months
PGF Stock 12 Month Forecast
Average Price Target
EUR 160.39▲(113.85% Upside)Based on 13 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is EUR 160.39 with a high forecast of EUR 196.92 and a low forecast of EUR 134.55. The average price target represents a 113.85% change from the last price of EUR 75.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 196.92
AverageEUR 160.39
LowEUR 134.55
Highest Price TargetHighestEUR 196.92Average Price TargetEUR 160.39Lowest Price TargetLowestEUR 134.55
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Alice Nettleton | UBS | EUR 163.95 | buy | 118.60%Upside | Reiterated | 11/10/26 | ||
| Brian Cheng | J.P. Morgan | EUR 132.76→EUR 134.55 | buy | 79.40%Upside | Assigned | 11/09/26 | ||
| Yun Zhong | Wedbush | EUR 154.15 | buy | 105.53%Upside | Reiterated | 11/09/26 | ||
| Evan Seigerman | BMO Capital | EUR 169.30 | buy | 125.73%Upside | Reiterated | 11/09/26 | ||
| Etzer Darout | Barclays | EUR 160.39 | buy | 113.85%Upside | Reiterated | 11/06/26 | ||
| Douglas Tsao | H.C. Wainwright | EUR 151.48→EUR 196.92 | buy | 162.56%Upside | Reiterated | 11/06/26 | ||
| Tara Bancroft | TD Cowen | EUR 138.11→EUR 142.57 | buy | 90.09%Upside | Reiterated | 10/21/26 | ||
| Geoff Meacham | Citi | EUR 162.17 | buy | 116.23%Upside | Reiterated | 10/15/26 | ||
| Will Soghikian | Leerink Partners | EUR 133.66→EUR 169.30 | buy | 125.73%Upside | Initiated | 10/12/26 | ||
| Srikripa Devarakonda | Truist Financial | ― | buy | ― | Reiterated | 09/01/26 | ||
| Jonathan Wolleben | Citizens JMP | EUR 147.02→EUR 151.48 | buy | 101.97%Upside | Reiterated | 08/31/26 | ||
| Kaveri Pohlman | Clear Street | EUR 154.15 | buy | 105.53%Upside | Reiterated | 08/31/26 | ||
| Richard Law CFA | Goldman Sachs | EUR 165.73 | buy | 120.98%Upside | Reiterated | 08/31/26 | ||
 Unknown AnalystNot Ranked | Jefferies | EUR 107.82 | buy | 43.75%Upside | Reiterated | 07/16/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Alice NettletonUBS | BuyReiteratedEUR 163.95 | 11/10/26 | 118.60%Upside | ||
| Brian ChengJ.P. Morgan | BuyAssignedEUR 132.76→EUR 134.55 | 11/09/26 | 79.40%Upside | ||
| Yun ZhongWedbush | BuyReiteratedEUR 154.15 | 11/09/26 | 105.53%Upside | ||
| Evan SeigermanBMO Capital | BuyReiteratedEUR 169.30 | 11/09/26 | 125.73%Upside | ||
| Etzer DaroutBarclays | BuyReiteratedEUR 160.39 | 11/06/26 | 113.85%Upside | ||
| Douglas TsaoH.C. Wainwright | BuyReiteratedEUR 151.48→EUR 196.92 | 11/06/26 | 162.56%Upside | ||
| Tara BancroftTD Cowen | BuyReiteratedEUR 138.11→EUR 142.57 | 10/21/26 | 90.09%Upside | ||
| Geoff MeachamCiti | BuyReiteratedEUR 162.17 | 10/15/26 | 116.23%Upside | ||
| Will SoghikianLeerink Partners | BuyInitiatedEUR 133.66→EUR 169.30 | 10/12/26 | 125.73%Upside | ||
| Srikripa DevarakondaTruist Financial | BuyReiterated | 09/01/26 | ― | ||
| Jonathan WollebenCitizens JMP | BuyReiteratedEUR 147.02→EUR 151.48 | 08/31/26 | 101.97%Upside | ||
| Kaveri PohlmanClear Street | BuyReiteratedEUR 154.15 | 08/31/26 | 105.53%Upside | ||
| Richard Law CFAGoldman Sachs | BuyReiteratedEUR 165.73 | 08/31/26 | 120.98%Upside | ||
| Unknown AnalystJefferiesNot Ranked | BuyReiteratedEUR 107.82 | 07/16/26 | 43.75%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Protagonist Therapeutics
3 Months
Success Rate15/18 ratings generated profit
83%
Average Return
+17.22%
Copying Brian Cheng's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +17.22% per trade.
1 Year
Success Rate17/18 ratings generated profit
94%
Average Return
+88.54%
Copying Yun Zhong's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +88.54% per trade.
2 Years
Success Rate17/18 ratings generated profit
94%
Average Return
+157.25%
Copying Brian Cheng's trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +157.25% per trade.
PGF Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 |
| Buy | 16 | 24 | 27 | 26 | 16 |
| Hold | 2 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 18 | 25 | 27 | 26 | 17 |
In the current month, PGF has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PGF average Analyst price target in the past 3 months is 160.39.
PGF Financial Forecast
HighEUR 1.68
ConsensusEUR -0.15
LowEUR -0.85
PGF Earnings Forecast
Next quarter’s earnings estimate for PGF is -EUR 0.15 with a range of -EUR 0.85 to EUR 1.68. The previous quarter’s EPS was EUR 2.75. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 145M
ConsensusEUR 40M
LowEUR 2.42M
PGF Sales Forecast
Next quarter’s sales forecast for PGF is EUR 39.97M with a range of EUR 2.42M to EUR 145.14M. The previous quarter’s sales results were EUR 245.69M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
PGF Stock Forecast FAQ
What is DE:PGF’s average 12-month price target, according to analysts?
Based on analyst ratings, Protagonist Therapeutics’s 12-month average price target is €160.39.
What is DE:PGF’s upside potential, based on the analysts’ average price target?
Protagonist Therapeutics has 113.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Protagonist Therapeutics a Buy, Sell or Hold?
Protagonist Therapeutics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
What is Protagonist Therapeutics’s share price target?
The average share price target for Protagonist Therapeutics is €160.39. This is based on 13 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €196.92, and the lowest forecast is €134.55. The average share price target represents a 113.85% increase from the current price of €75.
What do analysts say about Protagonist Therapeutics?
Protagonist Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Street analysts.
How can I buy shares of Protagonist Therapeutics?
To buy shares of DE:PGF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
